Business   

Ranbaxy gets USFDA nod for Augmentin

NEW DELHI SEPT. 18. Ranbaxy Laboratories has received the U.S. Food and Drug Administration (USFDA) approval for marketing the generic version of Glaxo's antibiotic drug Augmentin.

When contacted, company spokesperson confirmed the development but refused to make any further comment.

Earlier, company was apprehending a delay in the launch of the drug in the wake of GlaxoSmithKline's allegation of stealing the bacteria used in preparation of drug against Novartis and Ranbaxy.

US International Trade Commission has already instituted an investigation into Novartis AG's U.S. marketing of a generic form of the antibiotic as per the information available on agency's website.

Ranbaxy had projected Augmentin sales of 37 million dollars in the US market during 2003. — PTI

Printer friendly page  
Send this article to Friends by E-Mail

Business

News: Front Page | National | Southern States | Other States | International | Opinion | Business | Sport | Miscellaneous |
Advts: Classifieds | Employment | Obituary |

Stories in this Section

• Corporates should look beyond profit — HLL chief
• HLL's response to SEBI's charge
• TVSE to focus on transaction printing business
• Gold demand drops in April-June
• Infosys working on settling sexual harassment case
• Hero Motors launches `Smart' bike
• U.S. TDA grant for Reliance Infocomm
• Reliance ups stake in BSES
• Ranbaxy gets USFDA nod for Augmentin
• Global bearishness impacts BSE
• Rupee firms up
• Stock Market Index
• Bullion rates
• Exchange rates
• Wipro, NetCracker in OSS alliance
• Oracle's new system for Linux
• TCS expands banking solutions range
• Consign's content management tool

Copyright © 2002, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu